Affordable Access

deepdyve-link
Publisher Website

The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence.

Authors
  • Mooso, Benjamin A1
  • Vinall, Ruth L2
  • Mudryj, Maria3
  • Yap, Stanley A4
  • deVere White, Ralph W5
  • Ghosh, Paramita M6
  • 1 Research Service, Veterans Affairs Northern California Health Care System, Sacramento, California.
  • 2 California Northstate College of Pharmacy, Rancho Cordova, California.
  • 3 Research Service, Veterans Affairs Northern California Health Care System, Sacramento, California; Department of Medical Microbiology and Immunology, University of California-Davis, Sacramento, California.
  • 4 Research Service, Veterans Affairs Northern California Health Care System, Sacramento, California; Department of Urology, University of California-Davis, Sacramento, California.
  • 5 Department of Urology, University of California-Davis, Sacramento, California. Electronic address: [email protected]
  • 6 Research Service, Veterans Affairs Northern California Health Care System, Sacramento, California; Department of Biochemistry and Molecular Medicine, University of California-Davis, Sacramento, California; Department of Urology, University of California-Davis, Sacramento, California.
Type
Published Article
Journal
The Journal of urology
Publication Date
January 2015
Volume
193
Issue
1
Pages
19–29
Identifiers
DOI: 10.1016/j.juro.2014.07.121
PMID: 25158272
Source
Medline
Keywords
License
Unknown

Abstract

Clinical and preclinical studies show that for reasons not currently clear prior treatment with chemotherapeutic agents rendered patients with urothelial carcinoma with muscle invasive bladder cancer resistant to EGFR family inhibitors as well. However, EGFR family inhibitors may be of use in patients with no prior chemotherapy in whom EGFR or ERBB2 is over expressed.

Report this publication

Statistics

Seen <100 times